AlphaQuest LLC Increases Stock Position in Arcturus Therapeutics Holdings Inc. $ARCT

Key Points

• AlphaQuest LLC increased its stake in Arcturus Therapeutics by 394.0% in Q1, acquiring a total of 35,282 shares valued at $374,000.
• Analysts have mixed ratings for Arcturus Therapeutics, with Canaccord Genuity reducing their target price from $68.00 to $66.00 while eight analysts maintain a "Buy" rating and a consensus target price of $50.57.
• Arcturus Therapeutics reported a net loss of ($0.34) per share but exceeded revenue expectations with $28.30 million for the quarter, significantly higher than the consensus estimate of $17.64 million.

AlphaQuest LLC increased its position in shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT - Free Report) by 394.0% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 35,282 shares of the biotechnology company's stock after acquiring an additional 28,140 shares during the period. AlphaQuest LLC owned approximately 0.13% of Arcturus Therapeutics worth $374,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Ameriprise Financial Inc. increased its holdings in Arcturus Therapeutics by 5.0% during the 4th quarter. Ameriprise Financial Inc. now owns 18,613 shares of the biotechnology company's stock worth $316,000 after acquiring an additional 883 shares during the period. Tocqueville Asset Management L.P. increased its holdings in Arcturus Therapeutics by 4.5% during the 1st quarter. Tocqueville Asset Management L.P. now owns 23,400 shares of the biotechnology company's stock worth $248,000 after acquiring an additional 1,000 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its holdings in Arcturus Therapeutics by 9.2% during the 1st quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 14,693 shares of the biotechnology company's stock worth $156,000 after acquiring an additional 1,232 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Arcturus Therapeutics by 7.2% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,018 shares of the biotechnology company's stock worth $323,000 after buying an additional 1,279 shares during the last quarter. Finally, Byrne Asset Management LLC increased its holdings in shares of Arcturus Therapeutics by 89.8% in the 1st quarter. Byrne Asset Management LLC now owns 2,885 shares of the biotechnology company's stock worth $31,000 after buying an additional 1,365 shares during the last quarter. Institutional investors own 94.54% of the company's stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on ARCT. Wall Street Zen raised shares of Arcturus Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 9th. Canaccord Genuity Group decreased their price target on shares of Arcturus Therapeutics from $68.00 to $66.00 and set a "buy" rating on the stock in a report on Tuesday, May 13th. Citigroup reissued a "buy" rating and issued a $49.00 price target (up previously from $47.00) on shares of Arcturus Therapeutics in a report on Tuesday, August 12th. Wells Fargo & Company cut their price objective on shares of Arcturus Therapeutics from $45.00 to $42.00 and set an "overweight" rating for the company in a research note on Tuesday, August 12th. Finally, Scotiabank reaffirmed an "outperform" rating on shares of Arcturus Therapeutics in a research note on Wednesday, July 2nd. Eight analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $50.57.

Arcturus Therapeutics Stock Down 1.7%

Shares of Arcturus Therapeutics stock traded down $0.29 during trading on Monday, reaching $17.01. The company's stock had a trading volume of 523,401 shares, compared to its average volume of 745,347. Arcturus Therapeutics Holdings Inc. has a 52-week low of $8.04 and a 52-week high of $25.88. The company has a market cap of $461.99 million, a price-to-earnings ratio of -7.63 and a beta of 2.38. The firm's 50-day moving average is $14.58 and its two-hundred day moving average is $13.36.

Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last announced its quarterly earnings results on Monday, August 11th. The biotechnology company reported ($0.34) earnings per share for the quarter, beating the consensus estimate of ($1.11) by $0.77. The business had revenue of $28.30 million during the quarter, compared to analysts' expectations of $17.64 million. Arcturus Therapeutics had a negative net margin of 49.26% and a negative return on equity of 24.87%. On average, equities research analysts anticipate that Arcturus Therapeutics Holdings Inc. will post -2.22 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.